You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

81 search results for: symptoms

expert video

How Interdisciplinary Communication and Collaboration Can Overcome Challenges in CSU Patient Management

10 min

Dermatology

Drs. Kim and Saini discuss the importance of interdisciplinary communication and collaboration in overcoming challenges in CSU patient management.

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Infographic

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

10 min

Dermatology

This static infographic covers the clinical presentations, diagnostic challenges, and disease burden of bullous pemphigoid (BP), a chronic relapsing autoimmune skin disease. Review the steps of diagnosis, which include clinical assessment and laboratory work. Explore comorbidities associated with BP and how they impact patient quality of life.

expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

17 min

Dermatology

Prof. Sonja Ständer emphasizes the high patient burden of PN, and how this is influenced by patient needs and comorbidities. She discusses how emerging treatments are reducing patient burden.

expert video

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

50 min

Dermatology

Dr Chih-Ho Hong, Dr Sarina Elmariah, Dr Brian Kim, and Professor Sonja Ständer explored prurigo nodularis from definition to pathology and patient management.

expert video

How Should We Define and Classify Prurigo Nodularis?

13 min

Dermatology

Dr. Sarina Elmariah explains how to recognize and classify PN, using clinical examples and comparisons with related conditions. She then discusses PN assessment in clinical studies and practice, and the unmet needs in disease understanding and diagnosis.

expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

15 min

Dermatology

Dr. Brian Kim discusses the numerous contributors to PN pathophysiology, including type 2 inflammation, neuronal dysfunction, and dermal fibrosis, emphasizing the unique and overlapping roles of IL 31, IL-4 and IL-13 in its pathology.

expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

1 min

Dermatology

Dr. Stephan Weidinger talks about the role of biomarkers and their impact on clinical decision-making.

expert video

How Can We Explore the Concept of Disease Modification in Children With AD?

2 min

Dermatology

Dr. Lawrence Eichenfield discusses the concept of disease modification in children with AD.

Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

15 min

Type 2 Inflammation

Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care

expert video

What Could Remission Mean in AD?

1 min

Dermatology

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

10 min

Dermatology

Learn more about the guideline-based diagnosis of chronic spontaneous urticaria with this interactive patient case.

expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

1 min

Dermatology

Explore the impact of moderate-to-severe atopic dermatitis on sleep in pediatric patients – a short soundbite from EADV 2022.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SudanChange country/region